9 research outputs found
Stability and Release Kinetics of an Advanced Gliclazide-Cholic Acid Formulation: The Use of Artificial-Cell Microencapsulation in Slow Release Targeted Oral Delivery of Antidiabetics
Introduction: In previous studies carried out in our laboratory, a bile acid (BA) formulation exerted a hypoglycaemic effect in a rat model of type-1 diabetes (T1D). When the antidiabetic drug gliclazide (G) was added to the bile acid, it augmented the hypoglycaemic effect. In a recent study, we designed a new formulation of gliclazide-cholic acid (G-CA), with good structural properties, excipient compatibility and exhibits pseudoplastic-thixotropic characteristics. The aim of this study is to test the slow release and pH-controlled properties of this new formulation. The aim is also to examine the effect of CA on G release kinetics at various pH values and different temperatures. Method: Microencapsulation was carried out using our Buchi-based microencapsulating system developed in our laboratory. Using sodium alginate (SA) polymer, both formulations were prepared: G-SA (control) and G-CA-SA (test) at a constant ratio (1:3:30), respectively. Microcapsules were examined for efficiency, size, release kinetics, stability and swelling studies at pH 1.5, pH 3, pH 7.4 and pH 7.8 and temperatures of 20 and 30 °C. Results: The new formulation is further optimised by the addition of CA. CA reduced microcapsule swelling of the microcapsules at pH 7.8 and pH 3 at 30 °C and pH 3 at 20 °C, and, even though microcapsule size remains similar after CA addition, percent G release was enhanced at high pH values (pH 7.4 and pH 7.8, p < 0.01). Conclusion: The new formulation exhibits colon-targeted delivery and the addition of CA prolonged G release suggesting its suitability for the sustained and targeted delivery of G and CA to the lower intestine
Nanotechnology and Drug Delivery
Nowadays nanotechnology represents an expanding field that is providing powerfultools for the pharmaceutical industry such as polymeric, solid lipid, metallic, and magnetic NPs, liposomes, dendrimers, and other nanostructures. The development of nanopharmaceutics allows the understanding of some of the major mechanisms of current diseases on a molecular basis. Particularly, drug delivery mediated by nanosystems is relevant since NPs are able to reach the target organ and deliver the drug with a desirable profile according to the pathology needs, minimizing undesirable side effects. The main physicochemical properties of nanosystems are related with the increase in the surface-to-volume ratio of the particles, their permeability across biological barriers, and the surface modification of nanodevices. These parameters are relevant in drug loading and release and particularly for the targeted delivery to cells showing specific markers or receptors in the membrane surface.Fil: Islan, German Abel. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Centro CientĂfico TecnolĂłgico Conicet - La Plata. Centro de InvestigaciĂłn y Desarrollo en Fermentaciones Industriales. Universidad Nacional de La Plata. Facultad de Ciencias Exactas. Centro de InvestigaciĂłn y Desarrollo en Fermentaciones Industriales; ArgentinaFil: Martin Saldaña, Sergio. Gihon Laboratorios QuĂmicos SRL; ArgentinaFil: Chevalier, Merari Tumin. Gihon Laboratorios QuĂmicos SRL; ArgentinaFil: Alvarez, Vera Alejandra. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Centro CientĂfico TecnolĂłgico Conicet - Mar del Plata. Instituto de Investigaciones en Ciencia y TecnologĂa de Materiales. Universidad Nacional de Mar del Plata. Facultad de IngenierĂa. Instituto de Investigaciones en Ciencia y TecnologĂa de Materiales; ArgentinaFil: Castro, Guillermo Raul. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Centro CientĂfico TecnolĂłgico Conicet - La Plata. Centro de InvestigaciĂłn y Desarrollo en Fermentaciones Industriales. Universidad Nacional de La Plata. Facultad de Ciencias Exactas. Centro de InvestigaciĂłn y Desarrollo en Fermentaciones Industriales; Argentin